<p>Fosun Pharma (02196.HK) announced that its controlling subsidiary HENLIUS (02696.HK) has had its drug registration application for a new indication of Surufatinib Injection (trade name: Hansizhuang) accepted by the National Medical Products Administration. This new indication is for use in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant therapy for patients with resectable gastric cancer who are PD-L1 positive. The application has also been included in the priority review process</p>

02696

<p>Fosun Pharma announced that its controlling subsidiary HENLIUS has received acceptance from the National Medical Products Administration for the drug registration application of Surufatinib Injection (trade name: Hansizhuang) for a new indication (i.e., in combination with platinum-based chemotherapy as neoadjuvant therapy and postoperative adjuvant treatment for patients with resectable gastric cancer who are PD-L1 positive) and has been included in the priority review process</p>

HENLIUS's new indication drug registration application has been accepted